Wavelength Restricted Light Therapy for Fatigue in multiple Sclerosis: A Pilot Study
The goal of the present investigation is to evaluate the effectiveness of light therapy in treating fatigue and thereby improving quality of life in MS patients complaining of fatigue. Integrity of the RNFL may represent an important factor that determines treatment responsiveness. Our findings may be important in advancing our understanding of the structure and function of the circadian system, how the predilection for involvement of the anterior visual system in MS influences the pathophysiology of a restricted and eloquent tract system, the RHT. Our study will be a randomized, blinded, placebo controlled crossover trial of light therapy in fatigued MS patients.
1. Males and females between the ages of 18-70.
2. Diagnosis of relapsing forms of MS (according to the revised McDonald Criteria).
3. Complaint of fatigue by the patients, or a positive screening based on the modified fatigue impact scale (MFIS).
4. MFIS score >=37.
5. RNFL of both eyes (measured via Spectralis OCT) <75[MICRO-SYMBOL]m for group 1.
6. RNFL of both eyes (measured via Spectralis OCT) >=75[MICRO-SYMBOL]m for group 2.
7. EDSS score ≤7.